Echelon Wealth Partners analyst Douglas Loe is changing his rating on drug developer Arbutus Biopharma (Arbutus Biopharma Stock Quote, Chart … [Read more...] about It’s time to sell Arbutus Biopharma, says Echelon Wealth
Life Sciences
Content brought to you by:
The Cantech Letter Life Sciences section is brought to you by Relay Medical Corp. (CSNX:RELA). Relay is in the business of commercializing innovative technologies, protected by issued and pending patents, in the medical diagnostics and research field with an emphasis on In Vitro Diagnostics (IVD) and Point of Care Testing (POCT). Click on the logo for more info...
Profound Medical stock has a 204 per cent upside, says Raymond James
Raymond James analyst Rahul Sarugaser is staying bullish on biotech company Profound Medical Corp (Profound Medical Corp Stock Quote, Chart, News … [Read more...] about Profound Medical stock has a 204 per cent upside, says Raymond James
Theralase Technologies has a 256 per cent upside, says Mackie Research
Analyst André Uddin of Mackie Research says Theralase Technologies (Theralase Technologies Stock Quote, Chart, News TSXV:TLT) is targeting a … [Read more...] about Theralase Technologies has a 256 per cent upside, says Mackie Research
Medicenna Therapeutics has a huge upside, says Mackie Research
In an update to clients on Thursday, Mackie Research analyst André Uddin reports that a potential competitor drug to Medicenna Therapeutics’ … [Read more...] about Medicenna Therapeutics has a huge upside, says Mackie Research
Three Canadian Life Sciences stocks to watch for 2020
Canadian Life Sciences stocks have been on a roller coaster ride so far in 2019. The sector, which is comprised of drug and medical device … [Read more...] about Three Canadian Life Sciences stocks to watch for 2020
Biotech penny stock Antibe Therapeutics has a huge upside: Echelon
Echelon Wealth Partners analyst Douglas Loe is holding steady on his investment thesis for clinical stage drug developer Antibe Therapeutics (Antibe … [Read more...] about Biotech penny stock Antibe Therapeutics has a huge upside: Echelon
Raymond James launches coverage of Profound Medical Corp with a $4.00 target
Raymond James analyst Rahul Sarugaser thinks Profound Medical Corp (Profound Medical Corp Stock Quote, Chart, News TSX:PRN) is profoundly undervalued. … [Read more...] about Raymond James launches coverage of Profound Medical Corp with a $4.00 target
Biotech penny stock Kalytera Therapeutics has a huge upside, says Echelon
Echelon Wealth Partners analyst Douglas Loe calls the new update from Kalytera Therapeutics (Kalytera Therapeutics Stock Quote, Chart, News TSXV:KLY) … [Read more...] about Biotech penny stock Kalytera Therapeutics has a huge upside, says Echelon
Profound Medical is ready for a breakout, says Mackie Research
Investors should soon expect a breakout for Profound Medical Corp (Profound Medical Corp Stock Quote, Chart, News TSX:PRN) after the company’s … [Read more...] about Profound Medical is ready for a breakout, says Mackie Research
ProMetic Life Sciences has price target slashed at Echelon
Considerable losses and extended timelines for drug approval are keeping ProMetic Life Sciences (ProMetic Life Sciences Stock Quote, Chart, News … [Read more...] about ProMetic Life Sciences has price target slashed at Echelon
